You are viewing the site in preview mode
Skip to main content
|
Characteristics
|
All
|
Neurocognitively unimpaired N (%)
|
Neurocognitively impaired N (%)
|
p value
|
|---|
|
Demographics
|
|
Age [years, M (S.D.)]a
|
43.6 (09.6)
|
–
|
–
|
0.04
|
|
Genderb
|
|
Male [N (%)]
|
72 (74.2)
|
23 (31.9)
|
49 (68.1)
|
0.26
|
|
Female [N (%)]
|
25 (25.8)
|
05 (20.0)
|
20 (80.0)
|
|
Socioeconomic status [Kuppuswamy Scale] [N (%)]c
|
|
Lower
|
02 (02.1)
|
00 (00.0)
|
02 (100.0)
|
0.21
|
|
Upper lower
|
70 (72.2)
|
18 (25.7)
|
52 (74.3)
|
|
Lower middle
|
18 (18.6)
|
07 (38.9)
|
11 (61.1)
|
|
Upper middle
|
07 (07.2)
|
03 (42.9)
|
04 (57.1)
|
|
Upper
|
00 (00.0)
|
00 (00.0)
|
00 (00.0)
|
|
No. of years of education [M (S.D.)]a
|
10.9 (04.4)
|
–
|
–
|
0.68
|
|
Psychiatric characteristics [N (%)]
|
|
Mood symptoms (Based on Beck’s Depression Inventory)c
|
|
Normal
|
89 (91.8)
|
49 (55.1)
|
40 (44.9)
|
0.78
|
|
Mild mood disturbances
|
08 (08.2)
|
05 (62.5)
|
03 (37.5)
|
|
HIV disease characteristics
|
|
CD4 cell count [M (S.D.)]a
|
466.6 (189.2)
|
–
|
–
|
0.11
|
|
Nadir CD4 cell count [M (S.D.)]a
|
185 (54.1)
|
–
|
–
|
0.22
|
|
Diagnosed with AIDs [N (%)]c
| |
–
|
–
| |
|
Yes
|
13 (13.4)
|
00 (00.0)
|
13 (100.0)
|
0.98
|
|
No
|
84 (86.6)
|
28 (33.3)
|
56 (66.7)
|
|
Time since HIV diagnosis [M (S.D.)]a
|
08.4 (02.1)
|
-
|
-
|
0.67
|
|
ART statusc
|
|
On ART [N (%)]
|
95 (97.9)
|
27 (28.4)
|
68 (71.6)
|
0.58
|
|
Not on ART [N (%)]
|
02 (02.1)
|
01 (50.0)
|
01 (50.0)
|
|
Duration of ART (years) [M (S.D.)]a
|
2.6 (1.9)
|
–
|
–
|
0.94
|
|
Efavirenz-based treatment regimenb
| | | | |
|
N (%) On Efavirenz
|
49 (50.5)
|
14 (28.6)
|
35 (71.4)
|
0.79
|
|
N (%) Not on Efavirenz
|
46 (49.5)
|
12 (26.1)
|
34 (73.9)
|
|
ART regimen [N (%)]
|
|
TDF + 3TC + EFV
|
49 (50.5)
|
–
|
–
| |
|
AZT + 3TC + NVP
|
39 (40.2)
|
–
|
–
| |
|
AZT + 3TC + LPV/r
|
02 (02.1)
|
–
|
–
| |
|
AZT + 3TC + ABC
|
02 (02.1)
|
–
|
–
| |
|
TDF + 3TC + ABC
|
02 (02.1)
|
–
|
–
| |
|
TDF + 3TC + LPV/r
|
01 (01.0)
|
–
|
–
| |
- Statistical tests used are as follows
- TDF Tenofovir, 3TC Lamivudine, EFV Efavirenz, AZT Zidovudine, NVP Nevirapine, LPV/r Lopinavir-ritonavir, ABC Abacavir
- aIndependent sample t test, bChi Square Test, cFischer’s exact test
